FDA Sends Plan B Back to the Drawing Board

Ken Rankin
Published Online: Thursday, July 1, 2004

Community pharmacists will not be selling the controversial Plan B emergency contraceptive OTC—at least not this year. If the drug ever does win approval for nonprescription status, pharmacists may be called on to check the identity of purchasers.

Despite pressure from pro-choice groups to make the so-called "morningafter pill" available to women without a prescription, FDA officials raised concerns about the possible use of such a product by adolescent girls. In issuing a "Not Approvable" letter to Plan B sponsor Barr Laboratories, the FDA said that the company needs to conduct more research on the use of that product by girls younger than 16. "The sponsor's application contained no data on subjects under 14 years of age and very limited data on adolescents 14 to 16 years old," the agency letter said.

The FDA letter also said that Barr's application failed to include "adequate data to support use of Plan B by young adolescent women without the intervention of a physician."

The manufacturer is working to address the FDA's concerns. It is expected to issue a new proposal under which the drug would be sold OTC to women 16 and older, but by prescription only to those under 16.

Latest Articles
Pharmacists might be surprised to learn that Pinterest is a hotbed for anti-vaccine sentiment.
The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Latest Issues